Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.83
NRIFF's Cash to Debt is ranked higher than
63% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. NRIFF: 2.83 )
NRIFF' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 2.83

Equity to Asset 0.57
NRIFF's Equity to Asset is ranked higher than
64% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NRIFF: 0.57 )
NRIFF' s 10-Year Equity to Asset Range
Min: -0.42   Max: 0.99
Current: 0.57

-0.42
0.99
F-Score: 4
Z-Score: -13.18
M-Score: -3.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -22.13
NRIFF's Operating margin (%) is ranked higher than
77% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. NRIFF: -22.13 )
NRIFF' s 10-Year Operating margin (%) Range
Min: -1350.37   Max: 42.55
Current: -22.13

-1350.37
42.55
Net-margin (%) -56.37
NRIFF's Net-margin (%) is ranked higher than
72% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. NRIFF: -56.37 )
NRIFF' s 10-Year Net-margin (%) Range
Min: -1222.18   Max: 38.86
Current: -56.37

-1222.18
38.86
ROE (%) -85.08
NRIFF's ROE (%) is ranked higher than
57% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. NRIFF: -85.08 )
NRIFF' s 10-Year ROE (%) Range
Min: -414.89   Max: 40.09
Current: -85.08

-414.89
40.09
ROA (%) -48.00
NRIFF's ROA (%) is ranked higher than
61% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. NRIFF: -48.00 )
NRIFF' s 10-Year ROA (%) Range
Min: -281.51   Max: 30.93
Current: -48

-281.51
30.93
ROC (Joel Greenblatt) (%) -131.33
NRIFF's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. NRIFF: -131.33 )
NRIFF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2001.67   Max: 896.56
Current: -131.33

-2001.67
896.56
Revenue Growth (%) -8.00
NRIFF's Revenue Growth (%) is ranked higher than
70% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. NRIFF: -8.00 )
NRIFF' s 10-Year Revenue Growth (%) Range
Min: -37.7   Max: 48.7
Current: -8

-37.7
48.7
EBITDA Growth (%) -22.00
NRIFF's EBITDA Growth (%) is ranked higher than
64% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. NRIFF: -22.00 )
NRIFF' s 10-Year EBITDA Growth (%) Range
Min: -45.1   Max: 16.4
Current: -22

-45.1
16.4
EPS Growth (%) -17.30
NRIFF's EPS Growth (%) is ranked higher than
71% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. NRIFF: -17.30 )
NRIFF' s 10-Year EPS Growth (%) Range
Min: -54.5   Max: 17.3
Current: -17.3

-54.5
17.3
» NRIFF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NRIFF



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.30
NRIFF's P/B is ranked higher than
88% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. NRIFF: 2.30 )
NRIFF' s 10-Year P/B Range
Min: 0.71   Max: 44.43
Current: 2.3

0.71
44.43
P/S 1.30
NRIFF's P/S is ranked higher than
97% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. NRIFF: 1.30 )
NRIFF' s 10-Year P/S Range
Min: 0.77   Max: 39.13
Current: 1.3

0.77
39.13
EV-to-EBIT -4.75
NRIFF's EV-to-EBIT is ranked higher than
58% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NRIFF: -4.75 )
NRIFF' s 10-Year EV-to-EBIT Range
Min: 1.9   Max: 8.3
Current: -4.75

1.9
8.3
Current Ratio 2.87
NRIFF's Current Ratio is ranked higher than
67% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. NRIFF: 2.87 )
NRIFF' s 10-Year Current Ratio Range
Min: 0.14   Max: 25.02
Current: 2.87

0.14
25.02
Quick Ratio 2.64
NRIFF's Quick Ratio is ranked higher than
67% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. NRIFF: 2.64 )
NRIFF' s 10-Year Quick Ratio Range
Min: 0.05   Max: 23.62
Current: 2.64

0.05
23.62

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.70
NRIFF's Price/Net Cash is ranked higher than
89% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. NRIFF: 6.70 )
NRIFF' s 10-Year Price/Net Cash Range
Min: 2.53   Max: 931.23
Current: 6.7

2.53
931.23
Price/Net Current Asset Value 3.90
NRIFF's Price/Net Current Asset Value is ranked higher than
93% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. NRIFF: 3.90 )
NRIFF' s 10-Year Price/Net Current Asset Value Range
Min: 1.91   Max: 447.3
Current: 3.9

1.91
447.3
Price/Tangible Book 2.80
NRIFF's Price/Tangible Book is ranked higher than
89% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. NRIFF: 2.80 )
NRIFF' s 10-Year Price/Tangible Book Range
Min: 1.38   Max: 1917.5
Current: 2.8

1.38
1917.5
Price/Median PS Value 0.40
NRIFF's Price/Median PS Value is ranked higher than
96% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NRIFF: 0.40 )
NRIFF' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 121.81
Current: 0.4

0.27
121.81
Forward Rate of Return (Yacktman) -18.37
NRIFF's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. NRIFF: -18.37 )
NRIFF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -49.1   Max: -30.5
Current: -18.37

-49.1
-30.5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:NRI.Canada, DLAN.Germany
Nuvo Research, Inc. was incorporated on August 22, 1983 under the laws of the Province of Ontario as Clark Pharmaceutical Laboratories Ltd. The Company is a publicly traded Canadian specialty pharmaceutical company with manufacturing operations. The Company is building a portfolio of products for the treatment of pain through internal research and development (R&D) and by in-licensing and acquisition. Three of the pain products in its portfolio have been commercialized and the others are at varying stages of development. The Company's pain products are medications that are delivered into and through the skin. The Company is also involved in R&D activities with WF10, a chlorite-based immunomodulating drug, through Nuvo Research AG. The Company refers to and manages these activities as two distinct business and research segments: the Pain Group and the Immunology Group.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide